It would be great to hear from the science guys on what the GILD might mean for pphm"s virally. Logically speaking what is clear from all the different Bavi/viral data that has come out is that Bavi"s strenght seem to be safety and ability to help train the immune system.
I am hoping that the Hep C trial was more of an exploratory trial to see if Bavi could be a quick straight up shot in the dark all-inclusive replacement to INF. It does not appear it was when going against the straight up SOC 12 week design.
If Bavi is a candidate for HepC in the role of immune trainer or whatever it appears we will need to do an accross the board explore all the options assault via new trials with various drugs. It needs to bean all out ____ to the walls campaign. I think King knew this way before the data came out when they did the CC and he said (before the data was out) that we will be looking to license, partner, etc to a company whose focus was in HepC so we could use our resources to focus on Bavi/Cancer.
So in Summary, we were willing to take a quick inexpensive shot at HEPC on our own to see if we had a quick replacement to INF and current SOC but since we do not and the data they were seeing told them this months ago they were already to pass it along to a willing partner. The problem looks like due to the need for a wide net, with higher costs, I am not looking for much in the way of up front money.
AI
Market Data 
Markets 
